Trial Profile
Study of Apatinib in Patients With Local Advanced/Metastatic Iodine-131131I-Refractory/Resistant Differentiated Thyroid Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Aug 2021
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 09 Aug 2021 Status changed from active, no longer recruiting to completed.
- 26 Mar 2021 Results of long-term evaluation analysis published in the Journal of Clinical Endocrinology and Metabolism
- 06 May 2020 Status changed from completed to active, no longer recruiting.